8-K: Establishment Labs Posts Record Q4 Revenue, 27% FY25 Growth

Establishment Labs Holdings Inc. announced preliminary unaudited financial results for Q4 and fiscal year 2025, projecting record quarterly revenue and 27% annual growth.

Summary

• Preliminary unaudited revenue for Q4 2025 is expected to be between $64.0 million and $65.0 million.
• Motiva sales in the United States for Q4 2025 are expected to be between $17.0 million and $17.5 million.
• Full-year 2025 revenue is expected to be in the range of $210.5 million to $211.5 million.
• This represents an approximate 27% growth over 2024 full-year revenue.
• Motiva sales in the United States for fiscal year 2025 are expected to be between $45.4 million and $45.9 million.
• The year-end 2025 cash position is expected to be approximately $75.5 million, an increase of $4.8 million from the end of Q3 2025.

Sentiment

Score: 8

Explanation: The filing reports strong preliminary financial results, including record revenue and significant year-over-year growth. Management's forward-looking statements are highly optimistic, projecting continued growth, positive free cash flow, and increasing operating leverage. The increase in cash position further supports a positive outlook, despite the preliminary nature of the data.

Positives

• Record quarterly revenue expected for Q4 2025, ranging from $64.0 million to $65.0 million.
• Strong full-year 2025 revenue growth of approximately 27% over 2024, reaching $210.5 million to $211.5 million.
• Positive adjusted EBITDA continues.
• Cash position increased by $4.8 million from Q3 2025, reaching approximately $75.5 million at year-end 2025.
• Expectation to turn free cash flow positive later in 2026.
• Operating leverage is expected to become very evident in 2026 and beyond.

Risks

• Ability to successfully, timely, and cost-effectively develop, seek, and obtain regulatory clearance for, and commercialize product offerings.
• The rate of adoption of products by healthcare providers or other customers.
• The success of marketing initiatives.
• The safe and effective use of products.
• Ability to protect intellectual property.
• Future expansion plans and capital allocation.
• Ability to expand upon and/or secure sources of credit or capital.
• Ability to develop and maintain relationships with qualified suppliers to avoid significant interruptions in supply chains.
• Ability to attract and retain key personnel.
• Ability to scale operations to meet market demands.
• The effect on the business of existing and new regulatory requirements.
• Other economic and competitive factors.

Future Outlook

Management expects continued growth in 2026, with the business accelerating towards becoming the industry standard. The company anticipates turning free cash flow positive later in 2026 and expects operating leverage to become very evident in 2026 and beyond.

Management Comments

• "We had an excellent finish to 2025, with record quarterly revenue."
• "Growth will continue in 2026 as our business accelerates towards being the industry standard."
• "We continue to have positive adjusted EBITDA, and our cash position reflects our success in managing and improving the business."
• "We expect to turn free cash flow positive later this year, and our operating leverage will become very evident in 2026 and beyond."

Industry Context

Establishment Labs operates in the dynamic and growing medical technology sector, specifically focusing on breast aesthetics and reconstruction. The reported strong revenue growth of 27% for FY2025, coupled with positive adjusted EBITDA and an increasing cash position, indicates robust performance in a competitive market. The company's emphasis on innovation with products like Mia Femtech, Preserv, GEM, Motiva Flora, and Zensor, supported by extensive patent applications and clinical studies, positions it as a leader in advanced solutions for women's health and wellness. The expectation to become free cash flow positive in 2026 suggests a maturing business model with increasing operational efficiency, potentially outpacing some competitors still in earlier growth stages.

Comparison to Industry Standards

• The reported 27% revenue growth for FY2025 is strong for a medical device company, especially in a specialized segment like breast aesthetics and reconstruction. While specific comparable companies are not named in the filing, this growth rate generally exceeds the average for mature medical device markets, which often see single-digit to low double-digit growth.
• The company's focus on innovative, minimally invasive platforms like Mia Femtech and Preserv, along with advanced technologies such as the Motiva Flora tissue expander with integrated RF port and the Zensor RFID platform, positions it at the forefront of technological advancements in the industry. This commitment to R&D and intellectual property (over 200 patent applications) is a key differentiator compared to companies relying on older generation implants or less sophisticated monitoring systems.
• The expectation to achieve free cash flow positive status in 2026, following sustained positive adjusted EBITDA, indicates a strong financial trajectory. This is a critical milestone that many growth-stage medical technology companies strive for, demonstrating financial self-sufficiency and operational efficiency.

Stakeholder Impact

• Shareholders: Positive preliminary results and optimistic future outlook could lead to increased investor confidence and potential share price appreciation.
• Employees: Continued growth and strong financial performance suggest job security and potential for expansion.
• Customers (Surgeons/Patients): Continued innovation and product development (Mia Femtech, Preserv, Motiva Flora, Zensor) offer advanced solutions and improved outcomes in breast aesthetics and reconstruction.
• Suppliers: Increased demand due to growth may lead to higher order volumes for suppliers.
• Creditors: Improved financial health, positive adjusted EBITDA, and expected free cash flow positive status enhance the company's creditworthiness.

Next Steps

• Meetings at the J.P. Morgan Healthcare Conference during the week of January 12, 2026.
• Presenting full 2025 results on the February earnings call.
• Continuing business acceleration towards becoming the industry standard in 2026.
• Turning free cash flow positive later in 2026.
• Operating leverage becoming evident in 2026 and beyond.

Key Dates

Recommendation

The preliminary unaudited results indicate robust financial health with record Q4 revenue and substantial 27% year-over-year growth for FY2025. The company maintains a positive adjusted EBITDA and has increased its cash position. Management's outlook is highly optimistic, projecting continued acceleration, a shift to free cash flow positive status in 2026, and increasing operating leverage. These strong growth metrics, combined with a clear path to improved profitability and cash generation, suggest significant upside potential for investors. The company's innovative product pipeline and strong market position in a growing medical technology segment further support a 'strong buy' recommendation, especially given the preliminary nature of the positive results which often precede upward revisions or sustained positive momentum.

Keywords

Establishment Labs, ESTA, Medical Technology, Breast Aesthetics, Breast Reconstruction, Motiva, Mia Femtech, Preserv, GEM, Motiva Flora, Zensor, Financial Results, Revenue Growth, Cash Position, Q4 2025, FY 2025, Preliminary Results, SEC Filing